*Design target for technology in development. Sample-to-result time has not yet been established through completed clinical validation or regulatory review.
GLIA at a Glance
GLIA has moved beyond biomarker discovery and initial electrochemical proof of concept. Whole-blood miRNA measurement has been demonstrated, and the core outcomes of CSIRO's final development programme have now been successfully reproduced in an industry-based development environment. Current development is focused on integrating the assay, disposable cartridge, electronics and reader into the investigational point-of-care system.
Three Ways to Engage with GLIA
Select the pathway that best describes you — we'll pre-fill the enquiry form so you can reach the right conversation faster.
mTBI and concussion remain difficult to assess objectively — particularly when structural imaging is normal.
TBI affects over 69 million people globally each year. Clinical assessment remains central to diagnosis, while computed tomography (CT) is used principally to identify structural injury rather than diagnose concussion. Objective biological tools that can operate closer to the patient remain an important unmet need.
Clinicians on sports sidelines, military medics in the field and emergency physicians in regional hospitals may need to make important decisions without access to rapid, objective biological information. GLIA is being developed to help address that gap.
How It Works
Collect
Designed for PoC use without dependence on specialised central laboratory infrastructure.
Analyse
GLIA's proprietary platform is being developed to detect and quantify miRNA biomarkers associated with brain injury.
Know
Intended PoC system target result time: approximately 20 minutes (finger-prick whole blood, disposable cartridge, compact reader).
An important area of continuing investigation is whether serial miRNA measurement can help characterise the biological trajectory following injury and provide objective information relevant to recovery, subject to further clinical validation and regulatory clearance.
For sport and defence settings, GLIA is being developed to provide objective biological information that may complement clinical concussion assessment and future return-to-activity (RTA) decision-making.
GLIA's technology is based on a defined panel of circulating miRNAs investigated across human TBI studies. miRNAs are small regulatory RNA molecules involved in post-transcriptional control of gene expression and may provide biological information complementary to downstream protein biomarkers such as glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase L1 (UCH-L1).
The GLIA panel has been investigated across acute mTBI, persistent post-concussion symptoms, repetitive head impacts in sport and blast-related exposure. Current development is focused on translating this biomarker biology from laboratory-based molecular analysis into a practical whole-blood PoC format.
Grounded in Rigorous Molecular Science
GLIA's platform combines molecular biomarker research with pragmatic engineering to develop a tool intended to operate where and when it matters most — at the point of care.
Clinical Studies Completed
Five clinical studies completed, including four peer-reviewed publications, with further validation research planned or underway.⁹⁻¹²
Proprietary miRNA Biomarkers
Seven proprietary miRNA biomarkers supported by clinical research across acute traumatic brain injury, mild traumatic brain injury (mTBI)/concussion and longitudinal recovery cohorts. The panel is being investigated as a complementary molecular approach with potential utility across injury assessment, prognosis and recovery monitoring. The intended test does not rely on an individual pre-injury biomarker baseline.
PoC Platform
A compact handheld reader and single-use disposable cartridge are being developed to translate GLIA's earlier electrochemical proof-of-concept into an integrated PoC system. Whole-blood miRNA measurement has been demonstrated. Current development is focused on integrating that capability with the disposable cartridge and handheld reader into the investigational MVP.
Regulatory Pathway
GLIA has completed an independent regulatory strategy review and is preparing for U.S. Food and Drug Administration (FDA) Pre-Submission engagement to confirm intended use, predicate suitability, validation requirements and the appropriate regulatory pathway. Australian and European pathways will be progressed under the Therapeutic Goods Administration (TGA) framework and EU IVDR respectively.
A Formal Medical-Device Framework
GLIA is developing the PoC system within a formal medical-device development framework incorporating user needs, analytical performance, clinical evidence, usability engineering and risk management.
The initial intended use is being developed around providing objective biomarker information to support the assessment and management of suspected mTBI alongside existing clinical evaluation. Final indications for use, decision thresholds, clinical claims and labelling will be determined through analytical and clinical validation and regulatory engagement.
Human factors and risk-management activities are being incorporated early in development, with consideration of relevant U.S. Food and Drug Administration (FDA) guidance, IEC 62366-1 and ISO 14971.
Building a Body of Evidence
GLIA's technology has matured through a defined translational sequence: clinical biomarker evidence, electrochemical proof of concept, whole-blood miRNA measurement and successful replication of the outcomes documented in CSIRO's final product-development report in a new industry-based development environment. This strengthens evidence that the underlying sensor and assay technology can be transferred beyond its originating research setting. Development is now focused on integration, analytical characterisation and validation.
Clinical Studies
Five clinical studies completed, spanning acute traumatic brain injury, mTBI/concussion, longitudinal recovery, repetitive head impacts and blast-related exposure, with four peer-reviewed publications and further validation research planned or underway.
Peer-Reviewed Publications
Published and ongoing research evaluating the biological rationale and diagnostic/predictive performance of our miRNA biomarker panel.
Proprietary Biomarkers
Proprietary miRNA signatures identified and investigated based on observed associations with brain injury and biological relevance.
Plasma micro-RNA biomarkers for diagnosis and prognosis after traumatic brain injury: A pilot study.
Micro-RNA levels and symptom profile after mild traumatic brain injury: A longitudinal cohort study.
MicroRNA biomarkers for diagnosis of mild traumatic brain injury and prediction of persistent symptoms: A prospective cohort study.
MicroRNA Biomarkers on Day of Injury Among Patients with Post Concussive Symptoms at 28-Days: A Prospective Cohort Study.
Recent Technical Development Milestones
Whole-blood miRNA measurement has been demonstrated and the core outcomes of CSIRO's final development report have been successfully reproduced in an industry-based development environment, progressively de-risking the platform. Current development is focused on integrated product engineering, followed by analytical validation and regulatory engagement.
Whole-Blood Translation Demonstrated
GLIA has demonstrated measurement of its target miRNA biomarkers from whole blood, reducing a key sample-matrix translation risk in progression toward the intended fingerstick point-of-care workflow.
Industry-Based Replication of CSIRO Development Work
Following completion of the CSIRO development programme, GLIA transferred the sensor preparation, assay chemistry and electrochemical workflow into an industry-based development environment at Memjet. The core experimental outcomes documented in CSIRO's final product-development report were successfully reproduced in the new setting, demonstrating transferability and reproducibility beyond the originating controlled research environment. This represents an important translation milestone for GLIA, reducing dependence on the originating research environment and supporting progression toward integrated product engineering, analytical characterisation and future validation.
Next Value Inflection
Integration of the replicated assay and sensor workflow with the Genesys-developed electronics, cartridge and reader architecture, followed by analytical characterisation against established laboratory reference methods and progression toward FDA Pre-Submission engagement.
Advancing From Research to Point of Care
Advancing GLIA's clinically studied miRNA biomarkers toward an integrated investigational PoC platform.
- 01Biomarker Discovery & Clinical EvidenceFive clinical studies and peer-reviewed publications.
- 02Electrochemical Proof of ConceptDemonstrated electrochemical miRNA sensing and correlation with laboratory PCR.
- 03Whole-Blood miRNA MeasurementWhole-blood measurement demonstrated.
- 04CSIRO Development & Industry-Based ReplicationCore outcomes from CSIRO's final development report successfully reproduced in an industry-based development environment at Memjet.
- 01Integrated Product EngineeringIntegration of assay, cartridge, electronics and reader.
- 02Electronics & Reader DevelopmentGenesys engineering based on replicated electrochemical performance.
- 03Analytical CharacterisationPrecision, reproducibility, sensitivity, interference and correlation with laboratory reference methods.
- 04Whole-Blood Product QualificationProgression of the integrated system toward the intended fingerstick whole-blood workflow.
- 01FDA Pre-SubmissionTo align on the regulatory pathway.
- 02Clinical ValidationStudies in target populations.
- 03Regulatory SubmissionFor market authorisation.
- 04Scale-Up ManufacturingFor commercial readiness.
Roadmap reflects current priorities and may evolve based on technical, clinical, and regulatory developments.
Partnering with healthcare, defence, sport and industry to bring objective TBI diagnostics to the PoC.
Momentum From Research to Market
GLIA is currently seeking:
- Clinical and biobank partners for validation studies
- Strategic medtech and manufacturing collaborators
- Defence and sports organisations for future field studies
- Investors to support integrated product engineering, analytical validation and regulatory readiness
A Defensible Position for Translation
A triple-layer IP strategy: an exclusive worldwide licence covering the foundational miRNA biomarker family, plus two GLIA-owned patent families covering the PoC platform and diagnostic/prognostic methods. Existing protein biomarker tests address an important acute CT-triage need. GLIA is being developed as a complementary miRNA platform with potential applications in diagnosis, prognosis and longitudinal recovery monitoring, subject to further validation and regulatory clearance.
TRL 7 Biomarkers
Biomarker programme assessed at TRL 7; integrated device and cartridge development remain in progress.
Granted Patents
Granted across several jurisdictions covering the foundational biomarker technology.
Proprietary PoC IP
GLIA-owned electrochemical sensing and cartridge IP; PCT application filed with national/regional-phase applications entered in multiple jurisdictions.
MOU and Letters of Support
From multiple sporting codes spanning Australia and the US.
FDA Regulatory Strategy
FDA-cleared blood-based TBI tests provide relevant regulatory precedent. GLIA is preparing for Pre-Submission engagement to confirm its intended use, validation strategy and appropriate pathway.
GLIA has an established intellectual-property portfolio covering its TBI miRNA biomarkers and PoC technology, supported by granted patents, licensed intellectual property and additional filings across key international markets.
Complementary Biology, Investigated for mTBI
Current blood-based TBI diagnostics predominantly measure downstream protein biomarkers, including glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase L1 (UCH-L1). GLIA is developing a complementary approach based on circulating miRNAs — regulatory molecules involved upstream in biological pathways associated with the response to injury.
GLIA is developing a complementary biological approach based on circulating microRNA, with potential applications extending beyond acute structural injury triage into longitudinal assessment and recovery monitoring — investigating whether serial measurement can contribute to objective injury detection, prognosis and recovery assessment following mild traumatic brain injury (mTBI).
Alfred Hospital
CSIRO
Genesys
Macquarie University
Defence Research Engagement
US professional football organisation
Four Critical Use Settings
Emergency medicine is the primary clinical and regulatory pathway, with sport and defence serving as strategic validation and application environments, and remote and decentralised settings as future applications.
Emergency Medicine
The primary clinical and regulatory pathway: assessment of suspected mild traumatic brain injury (mTBI)/concussion, complementing established clinical assessment and existing diagnostic pathways, with rapid triage following head trauma.
Sport & Athletics
A strategic validation and application environment, including repetitive head impacts, serial assessment and recovery monitoring, complementing clinical concussion assessment.
Military & Defence
A strategic validation and application environment, including blast exposure, serial assessment and recovery monitoring, with potential future evaluation of rapid operational assessment and return-to-duty decisions.
Regional & Remote/Austere Health
A future decentralised application: rapid objective neurological assessment where applicable beyond hospital settings, including first response and communities where central laboratory and imaging infrastructure may be hours away.
Future expansion: aged care and community health settings.
Work With Us
GLIA is interested in collaborating with researchers, clinicians, defence organisations, sporting groups, diagnostic laboratories and technology partners working across TBI, blast exposure, biomarker biology, analytical validation and clinical translation.
Discuss a CollaborationPartner With Us
Progressing from successful industry-based technology replication into integrated product engineering and validation.
Current work is focused on optimising and validating whole-blood miRNA measurement, establishing analytical performance against laboratory reference methods, and integrating the assay with the disposable cartridge and reader platform.
- →FDA-cleared blood-based TBI tests provide relevant regulatory precedent.
- →Growing awareness of mTBI and brain health across sport and society.
- →Increased defence focus on blast exposure and Veteran brain health.
- →Growth of women's sport and increasing attention to sex-specific TBI research.
- →Rising demand for rapid diagnostics in regional and remote/austere settings.
Better access for the communities left behind.
Explore the technology.
Or partner with GLIA.
Learn how GLIA’s intended PoC system is being developed around a finger-prick whole-blood sample, disposable cartridge and compact reader, with a target result time of approximately 20 minutes.
Let's Start a Conversation
Whether you're a clinician, researcher, investor, or industry partner — we'd love to hear from you.
